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Introduction {#sec001}
============

Human Immunodeficiency Virus (HIV-1) remains a global health burden, with nearly 40 million people currently living with HIV. Treatment of infection is lifelong, due to the ability of the virus to establish latency by integrating its genome into that of host cells, which become quiescent and long-lived, resulting in the potential of viral reactivation at a future time \[[@ppat.1008679.ref001]--[@ppat.1008679.ref008]\]. By establishing latency, HIV evades eradication by host defense mechanisms and drug treatment. Following various stimuli including immune activation and "kick and kill" strategies, quiescent cells harboring virus become activated and the virus becomes transcriptionally active, resulting in production of viral proteins \[[@ppat.1008679.ref009], [@ppat.1008679.ref010]\]. Currently available antiretroviral therapies (ART) are able to control viral load but do not specifically target latent infection and have off-target effects in many individuals \[[@ppat.1008679.ref011]\]. For this reason, discovery of novel methods to target establishment of HIV infection and latency is crucial.

Currently implemented ART consists mainly of classes of drugs that target various stages of the viral life cycle, including inhibitors of entry, protease, integrase and reverse transcriptase \[[@ppat.1008679.ref011]\]. Another potential target to treat HIV infection is the use of immunomodulatory compounds directed toward a component of the immune system. This tactic could potentially have efficacy in a wide range of individuals and avoid some of the off-target effects observed with ART. Thus far, immunomodulatory compounds that target innate immune factors have not been extensively characterized for treatment of HIV. We were interested in examining the effect of modulation of the cellular signaling molecule Sphingosine-1-phosphate (S1P) on the establishment of productive as well as latent HIV infection. S1P is a lysophospholipid intra- and intercellular signaling molecule with a myriad of roles in the human body, including cell proliferation and migration, cytoskeleton rearrangement, membrane integrity, adhesion, survival/ apoptosis, and inflammation in nearly all cell types. These processes are modulated through the five receptors to S1P, known as S1PR1-5 (reviewed in \[[@ppat.1008679.ref012]\]). Although it is known that S1P receptor 1 (S1PR1) and S1P receptor 4 (S1PR4) are expressed on several subsets of CD4 T cells and can be modulated by various agonists and specific antagonists \[[@ppat.1008679.ref013]--[@ppat.1008679.ref015]\], the full spectrum of functions of S1P signaling in CD4 T cells, as well as the impact of HIV-1 infection on expression and activity of the S1P receptors, remains to be elucidated. The involvement of S1P in inflammation and various diseases is established \[[@ppat.1008679.ref012], [@ppat.1008679.ref016], [@ppat.1008679.ref017]\] and S1P signaling modulators have been studied extensively as potential cancer treatments \[[@ppat.1008679.ref018]--[@ppat.1008679.ref020]\], yet there is a paucity of knowledge of the role of S1P in HIV-1 pathogenesis.

FTY720, also known as Fingolimod or Gilenya, is an immunomodulatory compound that acts as a Sphingosine-1-phosphate receptor (S1PR) non-selective agonist and a selective antagonist of S1PR1 \[[@ppat.1008679.ref021]\]. FTY720 was initially synthesized using the naturally occurring fungal compound myriocin (ISP-1) as a lead \[[@ppat.1008679.ref022]\]. The compound is clinically approved for treatment of Multiple Sclerosis \[[@ppat.1008679.ref023], [@ppat.1008679.ref024]\] and is well-tolerated when taken orally on a daily basis \[[@ppat.1008679.ref025], [@ppat.1008679.ref026]\]. FTY720 has activity at four of the five S1P receptors (S1PR1, 3, 4 and 5) and has been shown to cause downregulation of S1PR1 in lymphocytes and act as a modulator of S1P signaling, effecting changes in chemotaxis, proliferation, and cell cycle state of lymphocytes and other cells \[[@ppat.1008679.ref015], [@ppat.1008679.ref021], [@ppat.1008679.ref027]--[@ppat.1008679.ref029]\]. In the case of S1PR1, FTY720 binds to this receptor when phosphorylated and causes its internalization and loss of signaling \[[@ppat.1008679.ref027]\].

It has been reported that S1PR1 is highly co-expressed with the HIV-1 coreceptor CCR5 on CD4 T cells and that targeting of S1PR1 reactivates HIV-1 from latency in an NF-κB-dependent manner \[[@ppat.1008679.ref014]\]. Recently, FTY720 has been shown to promote the retention of T cells in the lymph node in SIV-infected non-human primates with a subsequent reduction in the levels of SIV DNA in the blood \[[@ppat.1008679.ref030]\]. Further indicating an interplay between S1P signaling and progression of HIV infection, inhibition of glycosphingolipid metabolism was shown to impact susceptibility of CD4 T cells to infection \[[@ppat.1008679.ref031]\], and an impaired response to S1P and altered Akt signaling of lymph node CD4 T cells in chronically infected HIV-1 patients has also been observed \[[@ppat.1008679.ref032]\]. Due to the established clinical efficacy and safety of FTY720, we hypothesized that this immunomodulatory compound could potentially inhibit HIV infection. In this work, we report that modulation of the S1P receptors with FTY720 reduces the susceptibility of CD4 T cells to both productive and latent HIV infection in primary CD4 T cells and suggest the use of FTY720 as a potential novel adjuvant to treat HIV infection in prevention as well as curative strategies.

Results {#sec002}
=======

Functional antagonism of S1P signaling inhibits cell-free infection of HIV-1 {#sec003}
----------------------------------------------------------------------------

We first investigated the involvement of the S1P signaling pathway on establishment of productive HIV infection using a modification of our primary cell model of HIV (**[Fig 1A](#ppat.1008679.g001){ref-type="fig"}**), \[[@ppat.1008679.ref033]--[@ppat.1008679.ref035]\]. We isolated naïve CD4 T cells from PBMCs of HIV-negative human donors by negative selection and activated with αCD3/28 as previously described \[[@ppat.1008679.ref033]\]. Following activation, cells were expanded in culture with IL-2. To address the effects of FTY720 on cell-free HIV infection (**[Fig 1A](#ppat.1008679.g001){ref-type="fig"}**, left schematic), CD4 T cells were treated with FTY720 at day 5 of culture at a range of concentrations (30-100nM) for 48 hours. At day 7, cells were infected with either an X4- or R5-tropic HIV-1 (NL4-3 or NL-AD8, respectively). We assessed levels of infection by measuring p24-gag by flow cytometry 72 hours later (day 10). A representative flow cytometry analysis (of 7 donors, NL4-3 infected) is presented in **[Fig 1B](#ppat.1008679.g001){ref-type="fig"}**. We found that pre-treatment with FTY720 reduced HIV-1 infection in a dose-dependent manner with an average reduction of the frequency of infected cells for NL4-3 of 28.70+/-16.69%, 39.53+/-9.42%, 45.34+/-2.85% and 55.23+/-7.57% for 30nM, 44nM, 66nM and 100nM FTY720, respectively (**[Fig 1C](#ppat.1008679.g001){ref-type="fig"})**, and an average reduction of the frequency of infected cells for NL-AD8 of 31.75+/-13.91%, 32.16+/-9.95%, 41.60+/-12.57% and 41.12+/- 8.21% for 30nM, 44nM, 66nM and 100nM FTY720, respectively (**[Fig 1D](#ppat.1008679.g001){ref-type="fig"}**). Treatment with FTY720 did not alter viability at any of the concentrations examined (**[S1A and S1B Fig](#ppat.1008679.s001){ref-type="supplementary-material"}**) and the inhibitory efficacy of FTY720 was independent of viral tropism or strain (dose response curve, **[Fig 1E](#ppat.1008679.g001){ref-type="fig"})** and **[S2 Fig](#ppat.1008679.s002){ref-type="supplementary-material"}**.

![Functional antagonism of S1P signaling inhibits HIV infection.\
**A.** Primary T~CM~ model of HIV infection (left: infection at day 7 with FTY720 pre-treatment; right: infection at day 7 followed by crowding and FTY720 treatment day 10--13). **B.** Representative flow cytometry plot of HIV-gag p24 expression at day 10 following pre- treatment with increasing doses of FTY720 (0-100nM) from days 5--7 and 3 days of culture post spin-infection with NL4-3 at day 7. **C.** Summary of 48-hr FTY720 pre-treatment followed by spin infection with NL4-3 and three days of culture. Mean + Standard Deviation (SD) is plotted. Data from seven individual donors (p = 0.0156 for Untreated vs 30, 44, 66 and 100nM FTY720, Wilcoxon matched-pairs signed-rank test) are shown. **D.** Summary of 48-hr FTY720 pre-treatment followed by spin infection with NL-AD8 and three days of culture. Mean + SD is plotted. Data from seven individual donors (p = 0.0156 for Untreated vs 30, 44, 66 and 100nM FTY720, Wilcoxon matched-pairs signed-rank test) are shown. **E.** Dose response curve for FTY720 with NL4-3 and NL-AD8 cell-free infection expressed as the percentage of infected cells (p24+) versus concentration of FTY720. **F.** Representative donor (of 7 total donors) from productive infection (day 13); uninfected, NL4-3 infected (no treatment), and NL4-3 infected (66nM FTY720 during days 10--13). **G.** Frequency of infected cells (p24+) at day 13 following treatment during crowding from days 10--13 +/- 66nM FTY720; NL4-3 infected (no treatment) and NL4-3 infected (FTY720 during crowding). Mean + SD is plotted. Data from seven individual donors are shown; p = 0.0156 by Wilcoxon matched- pairs signed- rank test. **H.** Relative infection day 13; NL4-3 infected (no treatment) and NL4-3 infected (FTY720 during crowding). Data are representative of seven individual donors; p = 0.0156 by Wilcoxon's matched- pairs signed- rank test. Normalization was performed as follows: % relative infection = ((d13~treat~-d10~treat~)/(d13~untr~-d10~untr~))\*100.](ppat.1008679.g001){#ppat.1008679.g001}

Next, we investigated the effect of FTY720 on cell-to-cell transmission. To simulate cell-to-cell transmission, HIV-infected primary CD4 T cells were cultured in 96-well round bottom plates for three days (days 10--13, **[Fig 1A](#ppat.1008679.g001){ref-type="fig"}**, right schematic). We have previously shown that this procedure enhances cell-to-cell HIV transmission in primary CD4 T cells \[[@ppat.1008679.ref034]\]. In line with our cell-free infection results, we observed a marked decrease in productive infection with 66nM FTY720 following three days of culture as assessed by p24 at day 13 (**[Fig 1F](#ppat.1008679.g001){ref-type="fig"}**), with an average reduction in p24 of 54.4+/-16.02% (**[Fig 1G and 1H](#ppat.1008679.g001){ref-type="fig"}**, raw values and relative infection, respectively). This inhibition was, as for cell-free infection, not restricted to X4-tropic virus, as we saw a similar inhibition of cell-to-cell transmission with R5-tropic virus (**[S3 Fig](#ppat.1008679.s003){ref-type="supplementary-material"}**), and viability was not reduced over 72 hours in culture with FTY720 ([**S1A** and **S1C Fig**](#ppat.1008679.s001){ref-type="supplementary-material"}). In order to determine whether the inhibitory effect of FTY720 was due to an effect on infected (producer) cells, target cells, or both, we generated a co-culture system in which target CD4 T~CM~ were cultured with infected (producer) T~CM~. Target cells were pre-treated with 66nM FTY720 for 48 hours (the concentration used in cell-to-cell infection experiments), then labeled with Cell Trace Yellow dye immediately prior to co-culture with infected CD4 T cells. In parallel, untreated labelled targets were co-cultured with infected cells. Following 48 hours of co-culture, cells were harvested and infection assessed by flow cytometry. Intriguingly, in both donors we examined, the magnitude of the p24+ population in Cell Trace-labelled, pre-treated target cells was approximately 1/3 that of labelled, untreated cells (2.52 vs. 6.26 and 8.11 vs 24.3% p24+, respectively (representative donor, **[S4 Fig](#ppat.1008679.s004){ref-type="supplementary-material"}**). These results suggest that the inhibitory effect of FTY720 during cell-to-cell transmission is due to failure of HIV to infect the target cells rather than the inability of infected cells to produce virions. To verify this, we treated infected CD4 T~CM~ with 66nM FTY720 and ART (1μM Raltegravir and 0.5μM Nelfinavir) for 72 hours in order to prevent further rounds of infection and assessed p24 (viral release) by ELISA. We did not observe a difference in p24 production in the presence or absence of FTY720 during ART treatment, indicating that this S1P signaling modulator does not likely affect viral release in our model (**[S5 Fig](#ppat.1008679.s005){ref-type="supplementary-material"}**).

FTY720 reduces total and integrated HIV-1 DNA in T~CM~ {#sec004}
------------------------------------------------------

Using a primary cell model of latency, we have previously shown that latent infections are established during cell-to-cell transmission and the magnitude of latent infection directly correlates with productive infection measured at day 13 \[[@ppat.1008679.ref034], [@ppat.1008679.ref035]\]. Therefore, following our observation that FTY720 inhibits cell-free and cell-to-cell infection by HIV, we questioned whether pre-treatment with FTY720 (days 10--13) would lead to a reduction in levels of proviral DNA harbored within target cells and possibly to a reduction in the establishment of latency. To address this question, infected cells were treated with 66nM FTY720 from day 10 to 13. At day 13, FTY720 was removed from the culture and cells were cultured with 1μM Raltegravir and 0.5μM Nelfinavir from days 13 to 17 to block further viral spread. At day 17, we isolated the non-productively infected (CD4+) cells, which contain a mixture of uninfected and latently infected cells \[[@ppat.1008679.ref034]\]. At this point, latent HIV infection was assessed by measuring total and integrated HIV DNA via nested PCR as previously described \[[@ppat.1008679.ref036]\] (schematic, **[Fig 2A](#ppat.1008679.g002){ref-type="fig"}**). We found that treatment with FTY720 resulted in a reduction in both total and integrated HIV DNA at day 17 (approximately 51.45+/-3.19 and 60.41+/-19.59%, respectively, **[Fig 2B--2E](#ppat.1008679.g002){ref-type="fig"}**).

![FTY720 treatment reduces the establishment of latency and total and integrated HIV-1 DNA in T~CM~.\
**A.** Schematic of primary cell model of HIV latency. For **B-E**, all figures represent nested PCR performed on CD4+ T cells isolated at day 17 with no treatment or FTY720 (66nM) treatment from day 10--13; whether total or integrated HIV DNA. Data are representative of five individual donors. **B.** Total copies of HIV DNA per 10^6^ cells at day 17 (p = 0.0019, paired T-test). **C.** Relative total copies of HIV DNA per 10^6^ cells (total copies of HIV DNA in treated/ total copies of HIV DNA in untreated) at day 17 (p\<0.0001, paired T-test). **D.** Integrated copies of HIV DNA per 10^6^ cells at day 17 (p = 0.0374, paired T-test). **E.** Relative integrated copies of HIV DNA per 10^6^ cells (integrated copies of HIV DNA in treated/ integrated copies of HIV DNA in untreated) at day 17 (p = 0.0023, paired T-test). **F.** Representative donor from inducible latent HIV reactivation (day 19); untreated (IL-2 only), IL-2 + αCD3/28, IL-2 + FTY720 and FTY720 + αCD3/28. **G.** Frequency of infected cells (% p24+) at day 19 following CD3/28 stimulation days 17--19 with treatment during crowding from days 10--13 +/- 66nM FTY720; untreated (IL-2 only), IL-2 + αCD3/28, IL-2 + FTY720 and FTY720 + αCD3/28. Data is shown as Mean + Standard Deviation (SD). Data from seven individual donors, each with a unique symbol, are shown; p = 0.0156 for IL-2 only vs. αCD3/28 and αCD3/28 vs FTY720 + αCD3/28; p = ns for FTY720 + IL-2 vs FTY720 + αCD3/28, Wilcoxon matched-pairs signed-rank test for all comparisons. **H.** Relative % p24 upon reactivation by CD3/28 stimulation from days 17--19 (untreated or 66nM FTY720 treated from days 10 to 13, p = 0.0156, Wilcoxon matched-pairs signed-rank test). Normalization was performed as follows: % relative infection = ((d19~treat~-d17~treat~)/(d19~untr~-d17~untr~))\*100.](ppat.1008679.g002){#ppat.1008679.g002}

Next, we aimed to confirm that FTY720 interfered with the establishment of inducible latent HIV in CD4 T cells by assessing whether the reduction in the levels of HIV proviral DNA following FTY720 exposure translated to reduced reactivation of latent HIV. Latently infected cells were subjected to reactivation by TCR stimulation with αCD3/28 (or IL-2 only control) from days 17 to 19. TCR stimulation is one of the strongest stimuli that reactivates latent HIV in this model and in cells isolated from aviremic participants \[[@ppat.1008679.ref035], [@ppat.1008679.ref037]\]. As expected, the reduction of total and integrated HIV DNA due to FTY720 was accompanied by an average reduction in p24 following reactivation of 65.86+/-13.43% ([**Fig 2F, 2G** and **2H**](#ppat.1008679.g002){ref-type="fig"}) relative to untreated controls. Interestingly, when FTY720 was added along with ART from days 13--17, there was no significant difference in virus reactivated from latency at day 19, indicating that in this model latent infection is established prior to ART and following ART exposure the latent reservoir is not impacted by FTY720 (**[S6 Fig](#ppat.1008679.s006){ref-type="supplementary-material"}**). In light of our previous work demonstrating that in this model latently infected cells are established during cell-to-cell transmission, these results indicate that the brunt of the role of FTY720 on reduction of latency is likely a consequence of the reduction in productive infection. Overall, our results indicate that FTY720 not only reduces productive infection but that the effect is carried over into a reduced incidence of latently infected primary CD4 T cells.

FTY720 reduces binding and fusion of HIV-1 in T~CM~ {#sec005}
---------------------------------------------------

Next, we wished to address the mechanisms by which FTY720 inhibits HIV infection. Our results demonstrating that FTY720 reduced both total and integrated HIV DNA suggested that FTY720 inhibits HIV infection at a step prior to reverse transcription. Therefore, we first examined whether there was a block to infection during viral binding or fusion. To quantify binding, T~CM~ either pre-treated for 48 hours with 66nM FTY720 or untreated were incubated with NL4-3 (300ng p24) for 30 min at 4°C, then immediately lysed for p24 assessment by ELISA (modification of \[[@ppat.1008679.ref038], [@ppat.1008679.ref039]\]). We observed that in FTY720 pre-treated T~CM~ there was reduced virion binding in the majority of the donors tested (**[Fig 3A](#ppat.1008679.g003){ref-type="fig"}**, 8 of 9 donors, average reduction 23.32+/-16.99%). Next, we examined viral fusion using NL4-3-BLaM. This virus carries beta-lactamase-Vpr chimeric protein (BLaM-Vpr) which permits determination of virion-host cell membrane fusion based on cleavage of the substrate CCF2 upon virus entry \[[@ppat.1008679.ref040]\]. T~CM~ pre-treated with FTY720 or untreated were incubated with NL4-3-BLaM and cleaved substrate was assessed by flow cytometry. As with binding, we observed that in the majority (7 of 8) of donors accessed, there was a reduction in viral fusion in FTY720 pre-treated T~CM~ very similar to that of binding (**[Fig 3B--3D](#ppat.1008679.g003){ref-type="fig"}**, average reduction 24.23+/-26.00%). As HIV binding and fusion depend on expression and proper aggregation of CD4 and the co-receptor CXCR4 or CCR5 \[[@ppat.1008679.ref041]--[@ppat.1008679.ref047]\], we assessed the expression of CD4 in cells either treated with FTY720 or untreated for 48 hours. We did not observe a difference in percent expression of CD4 following 48 hours of FTY720 exposure; however, we did observe a significant reduction in the mean fluorescence intensity (MFI) of CD4 (**[Fig 3E](#ppat.1008679.g003){ref-type="fig"}**, average reduction 22.70+/-5.99%). Interestingly, the reduction in CD4 surface expression nearly matches that observed in both virion binding and fusion. There was not a statistically significant reduction in the MFI of CXCR4, but a significant reduction in the MFI of CCR5 on the CD4+ subset was observed ([**Fig 3F** and **3G**](#ppat.1008679.g003){ref-type="fig"}, respectively). Thus, FTY720 pre-treatment of T~CM~ results in a reduction of the surface density of CD4 that leads to a reduction in both binding and fusion. This reduction (average 23.52%) could only partially account for the strong reduction in integrated proviral HIV DNA observed (average 60.40%); thus, additional steps in the viral life cycle must be altered by FTY720 in CD4 T cells to account for the strong reduction in total and integrated HIV DNA.

![FTY720 reduces binding and fusion of HIV-1 to T~CM~.\
**A.** Relative NL4-3 binding to T~CM~ either untreated or pre-treated 48 hrs with 66nM FTY720 (n = 9, p = 0.0117 by Wilcoxon matched-pairs signed-rank test, treated values plotted as percent binding of untreated (pg/mL p24 in FTY720-treated/ pg/mL p24 in untreated)). **B.** NL4-3-BLaM fusion assay, two representative donors; uninfected, untreated NL4-3-BLaM infected and 66nM FTY720 + NL4-3-BLaM. **C.** Frequency of cells with HIV fusion events (%cleaved CCF2-A) in NL4-3-BLaM fusion assay (n = 8, p = 0.0234, Wilcoxon matched-pairs signed-rank test, raw values shown). **D.** Relative %cleaved CCF2-A for NL4-3-BLaM fusion assay (n = 8, p = 0.0234, Wilcoxon matched-pairs signed-rank test, treated values plotted as percent fusion events of untreated). **E.** Mean fluorescence intensity (MFI) of CD4 on CD4 T~CM~ either untreated or pre-treated 48 hrs with 66nM FTY720 (n = 12, p = 0.0002, Wilcoxon matched- pairs signed- rank test, violin plot with median and quartiles shown). **F.** MFI of CXCR4 within CD4 T~CM~ either untreated or pre-treated 48hrs with 66nM FTY720 (n = 7, p = 0.2877, Wilcoxon matched-pairs signed-rank test, violin plot with median and quartiles shown). **G.** MFI of CCR5 within CD4 T~CM~ either untreated or pre-treated 48hrs with 66nM FTY720 (n = 11, p = 0.001, Wilcoxon matched-pairs signed-rank test, violin plot with median and quartiles shown). For **E**-**G**, each donor is represented by a unique symbol and these symbols denote the same donor across the three plots.](ppat.1008679.g003){#ppat.1008679.g003}

FTY720 promotes a reduction in phosphorylated SAMHD1 concomitant with a reduction in Cyclin D3 {#sec006}
----------------------------------------------------------------------------------------------

As S1P signaling modulators have previously been shown to cause cell cycle arrest in other model systems \[[@ppat.1008679.ref048], [@ppat.1008679.ref049]\] and quiescent T cells have been observed to be relatively non-permissive to infection by HIV-1 \[[@ppat.1008679.ref001], [@ppat.1008679.ref050]\], we investigated the effect of FTY720 on cell cycle state in our primary cell model. We treated uninfected T~CM~ from day 10 of our model with 66nM FTY720 for 24, 48 and 72 hours and assessed cell cycle state by RNA/DNA staining (**[Fig 4A](#ppat.1008679.g004){ref-type="fig"}**, one representative donor of five) in order to mimic as closely as possible the phenotype of the cells from our model used for cell-to-cell transmission experiments. Following FTY720 treatment, we observed an increase in G0 (**[Fig 4B](#ppat.1008679.g004){ref-type="fig"}**) and G1b (**[Fig 4C](#ppat.1008679.g004){ref-type="fig"}**) stages and a concomitant reduction in S/G2 phase (**[Fig 4D](#ppat.1008679.g004){ref-type="fig"}**) starting from 24 hours post-treatment, which increased over time and was statistically significant at 48 and 72 hours (**[Fig 4D](#ppat.1008679.g004){ref-type="fig"}**). In agreement with an increase in G0 and decrease in S/G2 phases, we also observed a reduction in the proliferation marker Ki67 at 48 hours post-treatment of uninfected cells with 66-100nM FTY720 (**[Fig 4E and 4F](#ppat.1008679.g004){ref-type="fig"}**). The reduction in Ki67 with FTY720 treatment was also observed on infected cells (**[S7 Fig](#ppat.1008679.s007){ref-type="supplementary-material"}**).

![FTY720 promotes a quiescent state and reduction in proliferation in T~CM~.\
**A.** RNA (PyroninY) and DNA (7-AAD) stain of T~CM~ untreated or treated with FTY720 for 24, 48 and 72 hrs (one donor shown; representative of 5 donors). **B.** % G0 (PyroninY-/7-AAD-) T~CM~ in untreated (grey) or FTY720 treated (green) T~CM~ at 24, 48 and 72 hrs of culture (n = 5, Mean + Standard Error of Mean (SEM) shown). **C.** % G1b (PyroninY-/7-AAD+) in untreated (grey) or FTY720 treated (green) T~CM~ at 24, 48 and 72 hrs of culture (n = 5, Mean + SEM shown). **D.** % S/G2 (PyroninY+/7-AAD+) in untreated (grey) or FTY720 treated (green) T~CM~ at 24, 48 and 72 hrs of culture (n = 5, Mean + SEM shown, p = 0.028 for 48 hours and p = 0.044 for 72 hours by Multiple T test.). **E-F.** % Ki67+ cells in 48 hr untreated, 66nM FTY720 treated and 100nM FTY720 treated (all uninfected) T~CM~ (days 10--12 of culture). **E.** Representative staining of Ki67 in untreated (grey dotted line) and 66nM FTY720 treated (light green), overlay of histograms; and Ki67 in untreated (grey dotted line) and 100nM FTY720 treated (forest green), overlay of histograms. One representative donor of 8 (66nM) or 7 (100nM) total donors. **F.** % Ki67+ cells in 48 hr untreated, 66nM FTY720 treated and 100nM FTY720 treated (all uninfected) T~CM~ (days 10--12 of culture, p = 0.0078 and 0.0156 for 66 and 100nM, respectively, Wilcoxon matched-pairs signed-rank test, n = 7 or 8, Mean + SD shown).](ppat.1008679.g004){#ppat.1008679.g004}

Following our observation that FTY720 promotes a non-cycling state in T~CM~ and a reduction in total and integrated HIV DNA in our model, we hypothesized that FTY720 may be promoting the activity of an innate HIV restriction factor. SAM Domain and HD domain-containing protein 1 (SAMHD1) is an established HIV-1 restriction factor that impairs reverse transcription via control of the dNTP pool and has been shown to be modulated by various cell cycle-related kinases in proliferating and non-proliferating cells \[[@ppat.1008679.ref051], [@ppat.1008679.ref052]\]. Thus, we examined the effect of FTY720 on expression of total and phosphorylated (inactive) SAMHD1. We treated T~CM~ from day 10 of our model with 100nM FTY720 for 24 hours and quantified protein expression by Western blot. Following 24 hours of FTY720 treatment, we observed a significant reduction in pSAMHD1 (39.63+/-4.47%, [**Fig 5A** and **5B**](#ppat.1008679.g005){ref-type="fig"}) but did not observe an overall effect on total SAMHD1 levels ([**Fig 5A** and **5C**](#ppat.1008679.g005){ref-type="fig"}), indicating a relative increase in the active form of the restriction factor. SAMHD1 phosphorylation has been shown to be controlled by Cyclins and Cyclin-Dependent Kinases (CDKs) in primary human T cells and macrophages \[[@ppat.1008679.ref053]\];\[[@ppat.1008679.ref054]\]. Therefore, we evaluated whether FTY720 modulates the expression and phosphorylation of these kinases. We did not observe an effect on the levels of the majority of Cyclin-Dependent Kinases (CDKs) or Cyclins associated with transition from G1b to S phase of the cell cycle (CDK4, CDK6, Cyclin D2, CDK2, p21) or G2 to M phase (CDK1/pCDK1, **[Fig 6A--6I](#ppat.1008679.g006){ref-type="fig"}**); however, we observed a significant reduction in the levels of Cyclin D3 (46.89+/-14.61%, **[Fig 6J](#ppat.1008679.g006){ref-type="fig"}**, all blots and respective β-actin controls shown in **[S8 Fig](#ppat.1008679.s008){ref-type="supplementary-material"}**). Cyclin D3 has been demonstrated to regulate the activity of CDK6 and subsequently SAMHD1, the dNTP pool and HIV infection in macrophages \[[@ppat.1008679.ref055]\]. Our results indicate a relative increase in the active (non-phosphorylated) form of SAMHD1, which may be associated with the decrease we observed in Cyclin D3. The mechanism of the regulation of SAMHD1 in our primary cell model remains to be elucidated.

![Treatment with FTY720 induces a decrease in inactive (phosphorylated) SAMHD1.\
**A.** Phosphorylated and total SAMHD1 and β-actin control for two representative donors (one male, one female), untreated and 100nM FTY720-treated, with molecular weight of each protein indicated. **B.** Phosphorylated SAMHD1 in 24 hr untreated and FTY720 treated cultures, p = 0.0312, Wilcoxon matched-pairs signed-rank test (n = 6). Phosphorylated SAMHD1 is normalized to β-actin control and pSAMHD1 of the treated is plotted as a percentage of that of the untreated. **C.** Total SAMHD1 in 24 hr untreated and FTY720 treated cultures, p\>0.9999, Wilcoxon matched-pairs signed-rank test (n = 6). SAMHD1 is normalized to β-actin control and SAMHD1 of the treated is plotted as a percentage of that of the untreated.](ppat.1008679.g005){#ppat.1008679.g005}

![Alterations in Cyclin D3 are observed concomitantly with pSAMHD1 reduction.\
**A.** Representative Western Blot determination of protein levels of multiple Cyclin-Dependent kinases and Cyclins involved in cell cycle state, with molecular weight of each protein indicated. Shown are two representative donors of 6 total donors. **B-J.** Quantification of protein levels (by Western Blot) of the following Cyclin-Dependent Kinases, Cyclins or regulators of cell cycle, respectively: **B.** CDK1, **C.** pCDK1, **D.** CDK2, **E.** CDK4, **F.** CDK6, **G.** Cyclin D2, **H.** p21, **I.** p27, and **J.** Cyclin D3. p values displayed for Wilcoxon matched-pairs signed-rank test (all comparisons), n = 6 for all targets. For all proteins, the target is normalized to its respective β-actin control and expression of the treated is plotted as a percentage of that of the untreated.](ppat.1008679.g006){#ppat.1008679.g006}

FTY720 does not impact the efficacy of previously characterized Latency Reversal Agents {#sec007}
---------------------------------------------------------------------------------------

An S1PR1 specific agonist, SEW2871, has previously been shown to be a latency-reversing agent (LRA) in an *in vitro* model of resting PBMCs, and FTY720 also demonstrated modest, albeit non-significant, LRA activity \[[@ppat.1008679.ref014]\]. We therefore evaluated whether FTY720 could reactivate latent HIV alone or in combination with a panel of well-established LRAs with different mechanisms of action, including αCD3/28 (the positive control for latency reactivation in our model), the HDAC inhibitor SAHA (330nM), the TLR2/6 agonist Pam2CSK4 (1μM), the STAT SUMOylation inhibitor HODHBt (100μM) and the protein kinase C agonist Ingenol (100nM) \[[@ppat.1008679.ref056]--[@ppat.1008679.ref059]\]. We treated CD4 T cells isolated on day 17 of our model with 66nM FTY720 either alone or in combination with each LRA for 48 hours. The frequency of reactivated cells was measured by detection of the p24+ cells by flow cytometry. As can be seen in **[Fig 7](#ppat.1008679.g007){ref-type="fig"}**, FTY720 did not hinder the ability of any of the LRAs tested to reactivate HIV from latency and showed moderate latency reversal activity alone in some of the donors tested. These results suggest that FTY720 could be a novel potential adjuvant in "Shock-and-kill" cure strategies as it does not interfere with the action of other LRAs and blocks further rounds of productive infection.

![FTY720 does not impact the efficacy of previously characterized Latency Reversal Agents.\
CD4+ (non-productively infected) T~CM~ isolated at day 17 of our model of latency were cultured for 48hrs in the presence of 30 IU/mL IL-2 and a panel of several well-characterized Latency Reversal Agents (LRAs) alone or in combination with 66nM FTY720, including: the weak LRA/ control IL-2 only, αCD3/28 beads, SAHA (330nM), Pam2CSk4 (1μM), HODHBt (100μM) and Ingenol (100nM). Following the two days of culture each sample condition was accessed for the frequency of reactivated HIV (intracellular p24) by flow cytometry. For all LRAs, reactivation by each treatment is plotted as the percentage of the maximal stimulation in our model by αCD3/28, with each donor represented by a unique symbol (n = 5). Significance was determined by Wilcoxon matched- pairs signed- rank test for all comparisons.](ppat.1008679.g007){#ppat.1008679.g007}

Discussion {#sec008}
==========

In this study, we investigated whether targeting S1P could inhibit the establishment of HIV-1 infection and the generation of the latent reservoir in CD4 T cells. Prior to our work, others had observed the potential of an S1P receptor agonist to reactivate HIV from latency as well as a decreased response to S1P signaling in chronically infected individuals \[[@ppat.1008679.ref014], [@ppat.1008679.ref031], [@ppat.1008679.ref032]\]; however, the role of S1P signaling in establishment of infection and the potential to modulate this pathway to alter the course of infection or prevent establishment of the latent reservoir in CD4 T cells had not been reported.

Sphingolipids have been proposed to be involved in various stages of the HIV-1 life cycle \[[@ppat.1008679.ref031], [@ppat.1008679.ref060], [@ppat.1008679.ref061]\]. Sphingolipids are integral components of the cellular membrane \[[@ppat.1008679.ref062]--[@ppat.1008679.ref066]\] and inhibition of glycosphingolipids strongly reduces HIV-1 fusion and productive infection in cell lines and primary T cells, respectively \[[@ppat.1008679.ref031], [@ppat.1008679.ref067]\]. Various groups have proposed a key role for this class of lipids in entry of HIV-1 in CD4 T cells via stabilization of the gp120-CD4 interaction necessary for fusion \[[@ppat.1008679.ref068]--[@ppat.1008679.ref071]\]. We took advantage of the well-characterized, clinically approved S1P receptor modulator FTY720/Fingolimod, currently utilized for treatment of MS, to examine the potential role of S1P-S1P receptor signaling in HIV infection as well as in the establishment of latency. Our results demonstrate that the effects of FTY720 in HIV infection are multifactorial. First, FTY720 reduces the surface density of CD4 on T cells, supporting a partial repression of virion binding and fusion by FTY720. Although we observed a reduction in the MFI of CCR5 on CD4 T cells, likely due to its reported co-expression with S1P receptor 1 in primary CD4 T cells \[[@ppat.1008679.ref014]\], FTY720 inhibited infection irrespective of HIV-1 tropism, indicating a mechanism independent of coreceptor utilization. To our knowledge, there are no reports of CD4 and S1PR colocalization on CD4 T cells, although this could be a potential explanation of the reduction in MFI of CD4 observed. Alternately, the reduction in CD4 surface density could reflect the tendency that we observed of FTY720-treated cells to enter a resting state, or perhaps a destabilization of the cell membrane leading to less CD4 abundance, as glycosphingolipids have previously been implicated in other membrane interactions required for viral entry and fusion \[[@ppat.1008679.ref068]--[@ppat.1008679.ref071]\]. We propose a potential modulation by FTY720 of single or combined T cell surface features (CD4 abundance or distribution, lipid raft integrity, or stability of the viral synapse) resulting in the observed decrease in HIV binding and fusion. Our novel data indicate that there is yet much to uncover about the dynamics of membrane sphingolipids and HIV infection, as well as the potential regulation of membrane components by S1P modulators including FTY720.

As the blocks in viral binding and fusion together accounted for up to just 24% of the approximately 54% average reduction in productive HIV infection we observed, we examined additional stages of the HIV-1 life cycle to identify those which may be affected by modulation of S1P signaling. We measured the levels of total and integrated HIV-1 DNA by nested PCR and found that both forms were reduced (average of 51.45 and 60.41%, respectively) in FTY720-treated T~CM~ relative to untreated T~CM~. This result indicates that FTY720 inhibits infection at or prior to reverse transcription. This observation, along with our observation that T~CM~ in our model, when treated with FTY720, were encouraged toward a resting phenotype, led us to examine the effect of FTY720 on innate cellular restriction factors that may be differentially expressed across cell cycle states and contribute to inhibition of HIV-1 infection. We discovered that the phosphorylated form of SAMHD1, a deoxynucleoside triphosphate triphosphohydrolase that maintains cellular dNTP level balance and has also been shown to be an HIV-1 restriction factor \[[@ppat.1008679.ref051], [@ppat.1008679.ref052], [@ppat.1008679.ref072]\] was significantly reduced by FTY720 treatment in T~CM~ (average 39.6% reduction). Phosphorylated SAMHD1 is the inactive form of the restriction factor, thus, our observation of decreased levels of pSAMHD1 concomitant with maintenance of the total SAMHD1 availability indicates increased relative expression of the active form of this antiviral factor. SAMHD1 was first shown to restrict HIV-1 in myeloid and dendritic cells \[[@ppat.1008679.ref051]\] and was recently demonstrated to have an analogous role in macrophages \[[@ppat.1008679.ref073]--[@ppat.1008679.ref075]\] and CD4 T cells \[[@ppat.1008679.ref076]--[@ppat.1008679.ref078]\]. In CD4 T cells, a cyclin-binding motif on SAMHD1 is required for its restriction of HIV \[[@ppat.1008679.ref079]\] and its regulation by cell-cycle associated proteins including cyclins or Cyclin-Dependent Kinases (CDKs) has been demonstrated \[[@ppat.1008679.ref054], [@ppat.1008679.ref080]\]. In keeping with these reports, we observed a marked decrease in Cyclin D3 (average 46.98%) with FTY720 treatment along with increased relative expression of the active form of SAMHD1. Although Cyclin D3 has not yet been shown to interact with SAMHD1 in CD4 T cells as Cyclin A2 and Cyclin D2 have in other cell models \[[@ppat.1008679.ref079], [@ppat.1008679.ref081]\], this cyclin has been demonstrated to regulate SAMHD1 and subsequently permissiveness to HIV infection in macrophages \[[@ppat.1008679.ref055]\] and its expression was altered by FTY720 in a model of murine diabetes \[[@ppat.1008679.ref082]\]. As we also observed a reduction in S/G2 cell cycle phase and Ki67 expression in T~CM~ treated with FTY720, our results are consistent with a model of an FTY720-induced decrease in cell cycling along with a reduction of Cyclin D3 and potentially increased activity of SAMHD1. We therefore propose that Cyclin D3 may be a regulator of SAMHD1 activity in a cell-cycle dependent manner and that S1P signaling may regulate the levels of Cyclin D3 in CD4 T cells. Additional investigation will be needed to confirm this and determine whether this is a direct regulation by phosphorylation or whether other players are involved. Alternately, a different kinase may regulate activity of SAMHD1 via phosphorylation in T~CM~ and this kinase is inhibited by FTY720 in CD4 T cells.

Moreover, we aimed to determine the extent to which the effect of FTY720 observed during cell-free and cell-to-cell infection would impact reactivation of latent HIV. We observed a significant decrease in virus reactivated from latency in cells cultured with FTY720 from days 10 to 13, indicating that the ability of FTY720 to decrease infection translated to an inhibition of seeding of the latent reservoir. In fact, the decrease in latency was more potent than the effect on both cell-free and cell-to-cell infection (65.86% latency reduction vs 45.34 and 54.4% cell-free and cell-to-cell at 66nM FTY720, respectively). This decrease in infection level was supported by nested PCR results, which revealed a 60.4% reduction in integrated DNA. Thus, the reduction observed in integrated virus and the inhibition in the level of reactivation occur to approximately the same extent in our model. This suggests that FTY720 strongly reduces establishment of latency. Recently, Abrahams *et al* demonstrated that most latently infected cells are generated near the time of ART initiation \[[@ppat.1008679.ref083]\]. When we treated cells in our model with FTY720 concomitantly with ART, we readily observed reactivation of HIV, albeit no difference in FTY720-treated or untreated samples. Therefore, our results suggest that FTY720 may be useful as a strategy to limit the size of the latent reservoir if used prior to ART initiation, such as in acute infection. Finally, we examined whether FTY720 would interfere with the ability of a panel of established LRAs to reactivate latent HIV in our model. A previous report by Duquenne *et al* indicated that an S1PR1 agonist, SEW2871, could induce viral production in an *in vitro* model of HIV latency in resting PBMCs \[[@ppat.1008679.ref014]\]; however, in our primary cell model of latent HIV infection, we observed only weak LRA activity of FTY720 following 48 hours of culture, likely due to differences in the models used as well as differing mechanisms of FTY720 and other S1PR1 antagonists/ agonists. Importantly, we did not observe an impairment of the activity of several well-established LRAs in the presence of FTY720, indicating that FTY720 may be used in combination with other LRAs towards reducing the latent HIV reservoir.

In conclusion, our results indicate that FTY720 may be an exciting novel therapy for HIV infection. FTY720 is already clinically approved and well-tolerated and we show that it also restricts HIV infection of CD4 T cells. As such, targeting the S1P-S1PR axis may be an alternative strategy to employ in the context of prevention as a potential microbicide; as an adjuvant to current ART strategies to reduce the seeding of the latent reservoir; or in strategies aimed toward viral reactivation and eradication of the latent reservoir.

Materials and methods {#sec009}
=====================

Ethics statement {#sec010}
----------------

Cells were isolated from buffy coats of anonymous healthy blood donors obtained from the Gulf Coast Regional Blood Center (GCRBC) in Houston, Texas. GCRBC provided us with only the biological sex and age of donors. No other personal identifiable information (including race) was provided.

Reagents {#sec011}
--------

The following reagents were provided by the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID, MD): Nelfinavir (cat. \# 4621), Raltegravir (cat. \# 11680) from Merck & Company (NJ) and HIV-1~NLAD8~ and HIV-1~NL4-3~ from Malcolm Martin (MD, cat. \#s 11346 and 114). Human αIL-12 and αIL-4 were purchased through PeproTech (NJ). Human rIL-2 was obtained through the BRB/NCI Preclinical Repository (MD). Antibodies were purchased from BD (NJ, Kc57-FITC, CD4-APC), Biolegend (CA, Ki67), and eBiosciences (CA, eF450 fixable viability dye, CXCR4-PE-Cy5.5, CCR5-AF488). FTY720 (Fingolimod) was obtained from Cayman Chemical (MI, cat. \# 10006292, CAS\#162359-56-0).

Cell culture and generation of primary cell model of latency {#sec012}
------------------------------------------------------------

Human peripheral blood mononuclear cells were obtained from healthy, unidentified blood donors (Gulf Coast Regional Blood Center (GCRBC), TX). Naive CD4 T cells were isolated from PBMCs by negative selection and activated in non-polarizing conditions at 0.5x10^6^ cells/mL in the presence of 2μg/mL αhuman IL-12, 1μg/mL αhuman IL-4, 10ng/mL TGF-β and αCD3/28 stimulation beads at one bead/cell (Dynal/Invitrogen, CA) as previously performed \[[@ppat.1008679.ref033], [@ppat.1008679.ref034]\]. Subsequently, cells were expanded with 30 IU/mL hIL-2 in RPMI supplemented with 1% L-Glutamine, 10% Fetal Bovine Serum and 1% Penicillin/Streptomycin. Incubation with FTY720 was performed on cells from various time points of our model for 24--72 hours at concentrations of 30-100nM. HIV-1~NLAD8~ and HIV-1~NL4-3~ viruses were generated in HEK293FT cells by calcium phosphate transfection and latently infected cells were generated as previously described \[[@ppat.1008679.ref033], [@ppat.1008679.ref034]\].

For latency reversal experiments, cells were cultured at 0.5x10^6^ cells/mL in the presence of 30 IU/mL hIL-2. Reactivation conditions included: IL-2 only, 66nM FTY720, or one of the following LRAs +/- 66nM FTY720: αCD3/28 stimulation beads (one bead/cell), SAHA (330nM, Cayman), Pam2CSK4 (1μM, Invivogen), HODHBt (100μM, A.K. Scientific), or Ingenol (100nM, Cayman). Following 48 hours of culture, intracellular p24-gag was assessed by flow cytometry.

Flow cytometry {#sec013}
--------------

To analyze productively infected cells, 2.5x10^5^ cells were stained for CD4 (clone: S3.5, APC, BD), fixable viability dye (eF450, eBiosciences) and intracellular p24-gag (BD) and were analyzed on a Celesta flow cytometer (BD) as previously performed \[[@ppat.1008679.ref034]\]. For proliferation studies, cells were stained for CD4, viability and intracellular Ki67 (clone: 6604665, FITC, Biolegend). To analyze cellular RNA/ DNA content in order to determine cell cycle state, cells were stained with 7-AAD (Millipore Sigma, MA) and PyroninY (Sigma, MO) as previously done \[[@ppat.1008679.ref084]\]. To label cells prior to co-culture assays, cells were stained with Cell Trace Yellow proliferation dye (ThermoFisher, MA). Flow cytometry analysis was performed in FlowJo software (BD) and further statistical analysis was performed in GraphPad Prism (CA).

Quantitative real-time PCR for total and integrated HIV DNA {#sec014}
-----------------------------------------------------------

Nested PCR was performed as previously described \[[@ppat.1008679.ref036]\]. Briefly, CD4 T cells were digested with Proteinase K. A first round of PCR pre-amplification (12 cycles) was performed directly on cell lysates using primers for the LTR/*gag* region (total HIV DNA) or primers specific for the LTR region (ULF1) together with two *Alu* primers (integrated HIV DNA). A nested real-time PCR was then carried out on a Rotor-Gene Q instrument (Qiagen, Mississauga, Canada) using inner primers and a TaqMan probe. The number of copies of the *CD3* gene was determined to accurately quantify the number of cells in each reaction. Results were expressed as HIV DNA copies per 10^6^ CD3 T cells.

NL4-3-BLaM assay {#sec015}
----------------

T~CM~ were cultured for three hours with NL4-3-BLaM to determine viral fusion with the host cell membrane by incubation with beta-lactamase-Vpr chimeric proteins (BLaM-Vpr) substrate and flow cytometry as previously done \[[@ppat.1008679.ref040]\].

Protein analysis {#sec016}
----------------

To analyze protein expression, 10^7^ cells/mL were lysed in NETN lysis buffer (100mM NaCl, 20mM Tris-Cl (pH 8.0), 0.5mM EDTA, and 0.5% v/v Nonidet P-40 (NP40) supplemented with protease and phosphatase inhibitors (cOmplete mini, Millipore Sigma and PhosStop, Roche, Basel, Switzerland, respectively). Protein concentration was quantified by BCA assay and 10μg of both untreated and 100nM FTY720 pre-treated (24hr) sample were subjected to gel electrophoresis. Following transfer to nitrocellulose membrane, membranes were blotted with antibodies to phosphorylated and unphosphorylated SAMHD1 (cat. \# 89930S, cat. \# 12361), CDK1 (cat. \# 77095), pCDK1 (cat. \# 4539), CDK2 (cat. \# 2546), CDK4 (cat. \# 12790), CDK6 (cat. \# 3136), Cyclin D2 (cat. \# 3741), Cyclin D3 (cat. \# 2936), p27 (cat. \# 3686), and p21 (cat. \# 2947) plus β-actin control (cat. \# A5441), all from Cell Signaling Technologies (MA), followed by HRP-conjugated secondary antibody (cat. \#s 115-035-146 (α-mouse) and 111-035-046 (α-rabbit), both Jackson Immunoresearch, PA) and visualization with Immobilon HRP substrate (Millipore) and GeneGnome software (Syngene, Bangalore, India). Quantification was performed in GeneTools (Syngene).

Supporting information {#sec017}
======================

###### Viability of FTY720-treated T~CM~ A.

T~CM~ obtained by immunomagnetic isolation from PBMCs were cultured with 66nM FTY720 for 72hrs and viability was evaluated by fixable viability dye and Activated Caspase 3 staining. Representative donor staining of viability dye and activated Caspase 3 on T~CM~. **B-C.** T~CM~ obtained from naïve cells expanded in our primary cell model of latency were infected with NL4-3 or NL-AD8 and pre-treated +/-FTY720 (30--100 nM) and stained for flow cytometric assessment of viability at day 10 or 13. **B.** Viability of 7 donors infected with NL4-3 and 7 donors infected with NL-AD8 pre-treated +/-30-100nM FTY720 from day 5--7 and infected from day 7--10 (as in **[Fig 1A](#ppat.1008679.g001){ref-type="fig"}** left schematic). **C.** Viability of 7 total donors infected with NL4-3 at day 7 (as in **[Fig 1A](#ppat.1008679.g001){ref-type="fig"}** right schematic) and treated+/- 66nM FTY720 from day 10--13. For **B-C.**, Wilcoxon signed-rank matched-paired tests were used for all comparisons.

(TIF)

###### 

Click here for additional data file.

###### Infection of CD4 T cells with HIV 89.6 and JR-CSF

Primary CD4 T cells expanded and pre-treated at day 5 with 66 or 100nM FTY720 (as in **[Fig 1A](#ppat.1008679.g001){ref-type="fig"}**, left schematic) were infected with dual-tropic HIV-1 (89.6) or R5-tropic HIV-1 (JR-CSF) at day 7 of culture. Frequency of p24+ cells was assessed at day 10 by flow cytometry (N = 3 donors for each virus and each concentration of FTY720). **A.** Representative donor infected with 89.6 and JR-CSF, either untreated or treated with two concentrations of FTY720. **B.** Summary of infections with 89.6 and JR-CSF. Data are expressed as the percent of infection in the FTY720-treated conditions relative to untreated. Mean + SD are shown; statistical comparison was performed by paired T-test and is color coded for each virus (green = JR-CSF, purple = 89.6).

(TIF)

###### 

Click here for additional data file.

###### Functional antagonism of S1P signaling inhibits cell-to-cell transmission of R5-tropic HIV-1.

CD4 T cells were infected at day 7 with NL-AD8, crowded and treated with 66nM FTY720 from day 10--13, and assessed for frequency of infected cells by flow cytometry. **A.** Two representative donors from productive infection (day 13); uninfected, NL-AD8 infected (no treatment), and NL-AD8 infected (66nM FTY720 from day 10--13). **B.** Schematic of the experimental design. **C.** %p24+ cells at day 13 following treatment during crowding from day 10--13 with (or without) 66nM FTY720. Data comprise four total donors, each represented by a unique symbol. Statistical comparison was performed by paired T-test.

(TIF)

###### 

Click here for additional data file.

###### Co-culture of labeled FTY720-treated and NL4-3 infected T~CM~.

T~CM~ either treated or untreated with 66nM FTY720 for 48 hrs were labeled with Cell Trace Yellow dye and co-cultured with unlabeled pre-crowded NL4-3 infected (producer) T~CM~. 48hrs later, pre-treated and untreated target cells were evaluated for intracellular expression of p24 by flow cytometry, gating on Cell Trace Yellow+ cells. Shown is one representative donor of two individual donors (uninfected, untreated, and FTY720 pre-treated Cell Trace-labeled target cells and unlabeled producer cells.)

(TIF)

###### 

Click here for additional data file.

###### FTY720 treatment during ART does not alter viral release.

Primary CD4 T cells from our model were infected at day 7 and treated at day 10 with ART+/- 66 or 100nM FTY720, followed by assessment of p24-gag by ELISA at day 13 in order to determine the effect of FTY720 on viral release. **A.** Schematic of p24 ELISA following ART+/-FTY720 for 72 hours (days 10--13). **B.** Summary of p24 ELISA at day 13 following treatment of infected cells from day 10--13 with ART+/-FTY720 (either untreated or +FTY720, n = 4, statistical comparisons: paired T-test).

(TIF)

###### 

Click here for additional data file.

###### FTY720 treatment during ART does not alter reactivation from latency

Primary CD4 T cells from our model of HIV latency were infected with NL4-3 at day 7, crowded at day 10, uncrowded at day 13 and treated for 4 days with ART (1μM Raltegravir/ 0.5 μM Nelfinavir) in the presence or absence of 66nM FTY720 prior to isolation of non-productively infected (CD4+) cells at day 17 and reactivation of latent HIV-1 for 48 hours with αCD3/28 or IL-2 only control. Frequency of reactivated virus (%p24+ cells) was assessed by flow cytometry at day 19. **A.** Schematic of latency reversal following FTY720 treatment during ART. **B.** Two representative donors (of 4 individual donors) from day 19, following 48 hours of reactivation with αCD3/28 or IL-2 only control, either untreated or +66nM FTY720 from day 13--17. **C.** Summary of day 19 reactivation with αCD3/28 or IL-2 only control (either untreated or +66nM FTY720 from day 13--17, n = 4, both statistical comparisons: paired T-test). Mean is indicated and each donor is represented by a unique symbol.

(TIF)

###### 

Click here for additional data file.

###### Ki67 Expression on NL4-3 infected cells treated with FTY720.

Primary CD4 T cells were cultured and expanded, infected with NL4-3 at day 7, crowded at day 10 and treated or not treated with 66nM FTY720, and stained at day 13 for flow cytometry to assess the expression of the proliferation marker Ki67. Two infected donors were stained. Grey dotted line: uninfected/ untreated; green dotted line with light fill: uninfected + 66nM FTY720; pink dotted line: NL4-3 infected/ untreated; dark green filled histogram: NL4-3 infected + 66nM FTY720.

(TIF)

###### 

Click here for additional data file.

###### Western Blots of cell cycle proteins and β-actin controls.

Primary CD4 T cells (Cultured T Central Memory cells) were treated for 24 hours +/- 100nM FTY720 and were lysed for Western Blot determination of protein levels of multiple Cyclin-Dependent kinases and Cyclins. Shown are 6 total donors assayed for: CDK1, pCDK1, CDK2, CDK4, CDK6, Cyclin D2, p21, p27, Cyclin D3, pSAMHD1 and total SAMHD1, with the molecular weight of each protein indicated.

(TIF)

###### 

Click here for additional data file.
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Reviewer\'s Responses to Questions

**Part I - Summary**

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer \#1: The authors aim to describe the molecular mechanism through which FTY720 inhibits the viral life cycle. Unfortunately, in my view, the effects are weak and not very conclusive. Furthermore, while the use of primary cells is appreciated, in some figures (eg: 3B and D), this induces huge variability. I would recommend testing some of the hypothesis cited in the manuscript on additional models of HIV-1 infection, including cell lines and additional viral strains.

Reviewer \#2: Resop and colleagues study how Fingolimod (FTY720), a modulator of the S1P pathway, impacts HIV-1 replication. In an overall well-conducted, convincing and well-presented study, they show that FTY720 inhibits both cell-free and cell-to-cell infection. They demonstrate that this is due to multiple effects of the compound: downregulation of surface CD4 and CCR5, lower proliferative capacities and a higher relative expression of activated SAMHD1 (less pSAMHD1), likely due to the downregulation of CDK3, although no mechanistic link between the two is presented here. They further show that treatment with FTY720 leads to fewer latently infected cells, leading to fewer p24-expressing cells following reactivation. This is however expected as FTY720 decreases the levels of productively infected cells, a proportion of which becomes latently infected. They finally look at the latency reversal activity of FTY720, which only displays a poor effect by itself (if any), and doesn't modify the activity of the other latency reversal agents tested, which strengthen its potential role for shock and kill strategies. This interesting work is in line with previous studies examining the role of SP1R modulation during HIV-1, with a more virological and mechanistic point of view. Overall, this study provides evidence for the potential use of a FDA-approved drugs for HIV-1 treatment.

Reviewer \#3: In the manuscript, "Fingolimod inhibits multiple stages of the HIV-1 life cycle" Resop and colleagues investigated the effect of FTY720, a sphingosine-1-phosphate receptor antagonist on HIV infection. The authors reported that FTY720 is able to block HIV infection, by inhibiting viral binding and fusion and by increasing the activity of the viral restriction factor SAMHD1. This is a very well-written manuscript and highlights a novel target that could potentially be exploited to inhibit HIV replication. That said, the manuscript suffers from inconsistencies and made some claims that were not completely supported by the data presented. The strength of this manuscript can be significantly improved by addressing weaknesses outlined below.

1\. There is a general lack of important details with many of the figures. For example, in all figures with scatter plots, it is not really clear what is plotted. Mean + SD? Mean + range? How is the data normalized when relative percent are shown? This is especially important for the western blot figures 5 and 6. Is the data standardized to the loading control as it should be?

2\. The authors stated that \"FTY720 did not alter viability at any of the concentrations tested\" (line 129), but figure S1 only shows one concentration (66nM). Viability should be shown for all the concentrations.

3\. An important control for figure 2 should be an inclusion of viability data following treatment for 3 days with FTY720 to show that the reduction in HIV DNA is not due to cell death. Viability data in figure S1 is from 48hrs.

4\. Line 236, "we observed a significant reduction in pSAMHD1 (39.63 +/- 14.47%, Figs 5A and 5B) but did not observe an effect on total SAMHD1 levels (Figs 5C and 5D)". Can the authors comment on the fact that it appears that there are changes in total SAMHD1 levels (figure 5C), but perhaps inconsistent across the donors?

5\. Line 247, the authors state that that their results "results suggest a model of regulation of CDK4/6 by Cyclin D3, which in turn results in a decrease in phosphorylation and corresponding activation of the activity of the restriction factor SAMHD1" However, they did not really provide direct evidence of SAMHD1 activation. A functional assay showing SAMHD1 activation would be necessary to support their claim.

6\. Given that FTY720 is an immunomodulatory agent, and their data shows an effect on the cell cycle, including an increase towards a more resting, G0 phenotype following FTY720 treatment, can the authors comment on 1) the status of activation of their Tcm and how that might influence some of their results, including a limit in HIV infection and 2) the level of transcription factors necessary for efficient HIV transcription (e.g . P-TEFb) in cells treated with FTY720 and how that might also affect their observations on HIV infection ?

\*\*\*\*\*\*\*\*\*\*

**Part II -- Major Issues: Key Experiments Required for Acceptance**

Please use this section to detail the key new experiments or modifications of existing experiments that should be [absolutely]{.ul} required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a \"Major Revision\" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend \"Reject\".

Reviewer \#1: To validate their data, the authors should perform experiments in other models fo HIV infeciton, including either cell lines or additionnal virla stratins.

Reviewer \#2: Main concerns

1\) Figure 1: is there a control for the activity of FTY720 on SP1R? Which SP1R are important for the effects observed? At least, the authors should discuss which SP1R are expressed on CD4 T cells and how HIV-1 infection modulates their expression.

2\) In figure S1, it would be informative to show a graph with the viability for all donors and doses, especially the highest tested (100 nM).

3\) Figure 1 panel H should be placed before E, F and G as it is mentioned before in the text and concerns cell-free infection (which should be indicated in the legend).

4\) Figure 1 panel A schematic can be confusing and lead to the misleading interpretation that cells used for the cell-to-cell assay were used for the cell-free assay and treated twice with FTY720. Maybe splitting the schematic into two (one for cell-to-cell and one for cell-free) would be clearer. Moreover, as HIV-1 reactivation is assessed later in the manuscript, the experimental design could be rather added as a schematic in figure 2.

5\) For the cell-to-cell results of Figure 1E-G and Figure S2, showing the Gag/CD4 staining in the unlabeled producer cells would help strengthening the conclusion that FTY720 is mainly acting on target cells susceptibility to infection. Moreover, to study the effect of FTY720 on producer cells, infected cells could be cultivated in presence of ART +/- FTY720 and viral production in the supernatant assessed by a p24 ELISA. Are the effects on cell-to-cell transmission also independent of viral tropism?

6\) How many donors are the results presented in Figure S2 representative of? This should be added in the legend.

7\) The results presented in Figure 2 are somewhat expected. Indeed, it was shown in Figure 1 that the levels of infection at day 13 are lower when cells are treated with FTY720 during crowding. Thus, it is expected that after 4 days of ART, fewer cells will harbor HIV-1 DNA. Adding the compound during the ART treatment might help examining whether FTY720 modulates the seeding of the reservoir per se by examining the proportion of infected cells that will become latently infected.

8\) In panels A-D of figure 2, it seems surprising to reach p values of \<0.0001 with a Wilcoxon test on 5 donors.

9\) In panels A-D of figure 2, indicating whether we are looking at total or integrated DNA would make the figure clearer.

10\) Do they authors have any data or hypotheses for the mechanisms of downregulation of CD4 presented in Figure 3. This could be at least discussed.

11\) In figure 4, why did the authors wait until day 10 for treatment with FTY720?

12\) In figure 4 panels B, C and D, adding a legend (grey, green) on the figure would improve the readability and performing statistical analysis would strengthen the interpretation.

13\) Relative to Figure 4, in the context of infection, does treatment with FTY720 impact the cell cycle or proliferation of infected cells?

14\) To really look at the importance of SAMHD1 in the effects of FTY720, the authors could repeat the experiments in cells treated with VLP-Vpx. Looking at whether HIV-2 replication, which counteracts SAMHD1, is less inhibited by FTY720 could be of interest in a future study

15\) Panel 5D is redundant with 5B and 5C.

16\) Panel 6G title should be Cyclin D2 (space missing) and 6H should be p21 (not p27).

17\) Results presented in Figure 7 suggest that FTY720 is rather inactive for latency reversal. Repeating these experiments in ART-treated patients' samples would strengthen the conclusions on the role of FTY720 during latency reversal. Moreover, how may FTY720 modulate CD4 T cell activation? This could be discussed

18\) In the discussion, line 323, it is stated that there is an "increased expression of active SAMHD1". This should be changed to "relative expression" as what was observed is a lower expression of the inactive phosphorylated form.

19\) In the Methods section, line 409 should read "Results were expressed as HIV DNA copies per 106 CD3 T cells".

Reviewer \#3: 1. An important control for figure 2 should be an inclusion of viability data following treatment for 3 days with FTY720 to show that the reduction in HIV DNA is not due to cell death. Viability data in figure S1 is from 48hrs.

2\. Viability data for all concentrations of FTY720 should be included.

3\. The authors need to provide direct evidence to support their claim that FTY720 treatment results in an increase of activated SAMHD-1

\*\*\*\*\*\*\*\*\*\*

**Part III -- Minor Issues: Editorial and Data Presentation Modifications**

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer \#1: The viral titer should be quantified in some experiments (eg: Fig1) to show if the treatments affect virus production.

In Fig. 2: absolute number of copies should be presented.

In Fig. 3D: there is no visible change on the BLAM ssay for at least donor 1

In Fig. 4: show cell cycle profile

Reviewer \#2: (No Response)

Reviewer \#3: 1. Minor, but confusing, figure 1 in text not in sequence. 1B, 1C , 1D then 1H. Should be fixed.

2\. In figures with scatter, it would make it easier for the reader to evaluate the response across donors if a unique symbol is used for each donor.

3\. As western blot densitometry tracing is only semi-quantitative, the blots for all the donors should be included as a supplementary figure to better help the reader evaluate the data.

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plospathogens/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

[Figure Files:]{.ul}

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, [[https://pacev2.apexcovantage.com](https://pacev2.apexcovantage.com/)]{.ul}. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at [<figures@plos.org>]{.ul}.

[Data Requirements:]{.ul}

Please note that, as a condition of publication, PLOS\' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here on PLOS Biology: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>.

[Reproducibility:]{.ul}

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see [[http://journals.plos.org/plospathogens/s/submission-guidelines\#loc-materials-and-methods](http://journals.plos.org/plospathogens/s/submission-guidelines)]{.ul}
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23 May 2020

Dear PhD Bosque,

Thank you very much for submitting your manuscript \"Fingolimod inhibits multiple stages of the HIV-1 life cycle\" for consideration at PLOS Pathogens. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations. One of the reviewers has a few remaining very minor concerns which you should able to address easily.

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. 

When you are ready to resubmit, please upload the following:

\[1\] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript. 

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

\[2\] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don\'t hesitate to contact us if you have any questions or comments.

Sincerely,

Daniel C. Douek

Associate Editor

PLOS Pathogens

Susan Ross

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

​[orcid.org/0000-0001-5065-158X](http://orcid.org/0000-0001-5065-158X)

Michael Malim

Editor-in-Chief

PLOS Pathogens

[orcid.org/0000-0002-7699-2064](http://orcid.org/0000-0002-7699-2064)

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Reviewer Comments (if any, and for reference):

Reviewer\'s Responses to Questions

**Part I - Summary**

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer \#2: The authors have taken into account my concerns and the manuscript has been strongly improved. The addition of more background about FTY720 and SP1R is appreciated, as well as the addition of experiments suggested by the reviewers. These novel results, together with modifications of text and figures make the overall message clearer. Some minor remaining points can be found below.

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

**Part II -- Major Issues: Key Experiments Required for Acceptance**

Please use this section to detail the key new experiments or modifications of existing experiments that should be [absolutely]{.ul} required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a \"Major Revision\" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend \"Reject\".

Reviewer \#2: (No Response)

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

**Part III -- Minor Issues: Editorial and Data Presentation Modifications**

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer \#2: 1) In Figure S2B and S3C, include statistics. In Figure S5B and S6C legend, the statistical test performed should be indicated. Indeed, in most of the manuscript, Wilcoxon tests are used, but with 4 donors here, it is not possible to use such a test.

2\) Although the new Fig S7 is appreciated, an overlay of 4 histograms is difficult to read. Maybe presenting an offset histogram or plotting the Ki67+ percentages would make this figure clearer.

3\) In the abstract: "FTY720 reduces establishment of latent HIV infection" might be confusing given the new Fig S6 that shows that FTY720 does not impair the seeding of the viral reservoir per se. This could be rephrased to avoid any confusion.

4\) The description of Fig 2 is sometimes misleading. Indeed, the reduction in integrated HIV DNA at day 17 and the decrease of p24+ cells upon reactivation at day 19 may be the consequence of the lower levels of productive infection observed at day 10 and 13. Concluding that FTY720 leads to "a reduction of the seeding of the latent reservoir in primary CD4 T cells" may be an over statement, given the results of Fig S6. The authors should discuss that the reduction is likely a consequence of a lower productive infection rather than seeding of the reservoir.

5\) In the description of Fig S6 in the text, the authors may mention that the results indicate that in this model, latency is established during ART but is not impacted by FTY720.

6\) Similarly, in the discussion "Therefore, our results suggest that FTY720 may be useful as a strategy to limit the size of the latent reservoir if used concomitantly with ART initiation". This hypothesis is not supported by the novel Fig S6.

7\) In Fig 3, presenting examples of fusion plots before the graph with all the donors would facilitate reading. Fig 3B and 3C are somewhat redundant.

8\) In Fig 5A and 6A, blot images should be surrounded with a black line to make cuts clearer. Plaese assign the molecular weights to the corresponding panel. Molecular weights should be added in Fig 6A and S8.

9\) The authors should discuss the differences with the study of Duquenne C et al. (2017) where it was shown that S1PR1 agonists reverse latency, contrary to the results presented here.

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plospathogens/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, [[https://pacev2.apexcovantage.com](https://pacev2.apexcovantage.com/)]{.ul}. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at [<figures@plos.org>]{.ul}.

[Data Requirements:]{.ul}

Please note that, as a condition of publication, PLOS\' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>.

[Reproducibility:]{.ul}

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see [[http://journals.plos.org/plospathogens/s/submission-guidelines\#loc-materials-and-methods](http://journals.plos.org/plospathogens/s/submission-guidelines)]{.ul}
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3 Jun 2020

Dear PhD Bosque,

We are pleased to inform you that your manuscript \'Fingolimod inhibits multiple stages of the HIV-1 life cycle\' has been provisionally accepted for publication in PLOS Pathogens.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Daniel C. Douek

Associate Editor

PLOS Pathogens

Susan Ross

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens
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Michael Malim

Editor-in-Chief

PLOS Pathogens

[orcid.org/0000-0002-7699-2064](http://orcid.org/0000-0002-7699-2064)
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13 Jul 2020

Dear PhD Bosque,

We are delighted to inform you that your manuscript, \"Fingolimod inhibits multiple stages of the HIV-1 life cycle,\" has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc\...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

​[orcid.org/0000-0001-5065-158X](http://orcid.org/0000-0001-5065-158X)

Michael Malim

Editor-in-Chief

PLOS Pathogens

[orcid.org/0000-0002-7699-2064](http://orcid.org/0000-0002-7699-2064)
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